Jafron Biomedical Co

Jafron Biomedical Co CROIC

The Cash Return on Invested Capital (CROIC) of Jafron Biomedical Co (300529.SZ) as of Oct 17, 2026 is 11.79 %. In the previous year, Cash Return on Invested Capital (CROIC) was 18.02 % — a change of -34.61% (lower).

CROIC

11.79 %

YoY

-34.61%

Last updated:

Cash Return on Invested Capital (CROIC) of Jafron Biomedical Co is 2025 11.79 % . Cash Return on Invested Capital (CROIC) of Jafron Biomedical Co was 2024 18.02 % . It decreases by -34.61% lower compared to the previous year.

The Jafron Biomedical Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
11.66 CNY
Jan 1, 2019
16.48 CNY
Jan 1, 2020
21.16 CNY
Jan 1, 2021
16.65 CNY
Jan 1, 2022
8.41 CNY
Jan 1, 2023
13.94 CNY
Jan 1, 2024
18.02 CNY
Jan 1, 2025
11.79 CNY
The Jafron Biomedical Co CROIC history
YEARCROICYoY
11.79 %-34.61%
18.02 %+29.28%
13.94 %+65.78%
8.41 %-49.49%
16.65 %-21.32%
21.16 %+28.44%
16.48 %+41.30%
11.66 %+41.04%
8.27 %-34.73%
12.67 %-50.31%
25.49 %+57.83%
16.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co Ltd is a China-based health care company headquartered in Zhuhai. The company focuses on the research, development, production, and sale of hemoperfusion products. It went public on August 2, 2016, with its stock listed under ticker 300529.SZ and ISIN CNE100002995. Jafron employs 3,003 full-time staff and operates within the health care sector. Its products include disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resin bandages. These products are used in treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. Jafron's products are distributed across more than 3,000 hospitals in all 31 provinces of China. The company's website is https://www.jafron.com/. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Cash Return on Invested Capital (CROIC) of Jafron Biomedical Co is 11.79 % in 2025.

Cash Return on Invested Capital (CROIC) of Jafron Biomedical Co changed from 18.02 % to 11.79 %, representing a -34.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Jafron Biomedical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Jafron Biomedical Co